How Should an IBD Prevention Trial Be Designed?
- 24 September 2025
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (Supplement) , S61-S70
Abstract
Background: Advances in understanding disease pathogenesis have revealed a preclinical phase of inflammatory bowel disease (IBD), offering a potential window for preventive measures. There is growing interest in trials to prevent IBD in at-risk individuals. However, there is limited guidance on how to set up prevention trials in IBD. This review aims to outline key considerations for designing an IBD prevention trial. Methods: We conducted a review of the literature, gaining insight from prevention trials in other immune-mediated inflammatory diseases (IMIDs). We focused on considerations to set up a secondary prevention trial regarding design, risk stratification and selection strategies, inclusion and exclusion criteria, endpoints, and ethical considerations. Results: Across IMIDs in which features predictive of future risk have been identified, trials have leveraged well-characterized at-risk cohorts, biomarkers for disease prediction, and feasible interventions. Key elements to consider include (1) identification and longitudinal monitoring of at-risk individuals based on biomarkers, (2) clear definitions of inclusion and exclusion criteria distinguishing a primary prevention trial to prevent disease in at-risk individuals from a secondary prevention trial in individuals with signs of subclinical disease, (3) use of time-to-event endpoints, (4) risk-benefit balancing in intervention choice, and (5) engagement of at-risk individuals. In IBD, analogous strategies are emerging and first-degree relatives stand out as a group for screening. Significant challenges remain in defining risk thresholds, optimizing endpoints, and selected interventions. Conclusion: Prevention trials in IBD hold promise but require careful design informed by experiences from other IMIDs. Central to this effort are the development of validated predictive tools, ethically appropriate interventions, and international collaboration to assemble well-powered at-risk cohorts.Keywords
This publication has 56 references indexed in Scilit:
- Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated SyndromeJAMA Neurology, 2023
- Preclinical Serological Signatures are Associated With Complicated Crohn’s Disease Phenotype at DiagnosisClinical Gastroenterology and Hepatology, 2023
- Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated SyndromeAnnals of Neurology, 2022
- Implications of the changing epidemiology of inflammatory bowel disease in a changing worldUnited European Gastroenterology Journal, 2022
- Preferences and Insights for Participation in a Rheumatoid Arthritis Clinical Prevention Trial: A Mixed‐Methods StudyACR Open Rheumatology, 2022
- Genetic and Inflammatory Biomarkers Classify Small Intestine Inflammation in Asymptomatic First-degree Relatives of Patients With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2020
- I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid ArthritisArthritis Care & Research, 2019
- Increased Intestinal Permeability in Relatives of Patients With Crohn’s Disease Is Not Associated With Small Bowel UlcerationsClinical Gastroenterology and Hepatology, 2017
- Changes in T‐cell subsets identify responders to FcR‐nonbinding anti‐CD3 mAb (teplizumab) in patients with type 1 diabetesEuropean Journal of Immunology, 2015
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011